Search research articles
Contact Us
Filters
Showing results (71-80 of 132) with videos related to
Page
of 14
Sort By:
The Lancet. Gastroenterology & Hepatology
|
June 20, 2024
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
Harry L A Janssen, Young-Suk Lim, Pietro Lampertico, et al.
Journal of Gastroenterology and Hepatology
|
November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Yun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Alimentary Pharmacology & Therapeutics
|
October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks
Scott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Journal of Medical Virology
|
January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic Fibrosis
Yu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Nature Medicine
|
June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Stephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Gut
|
January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease
Yu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
The Lancet. Gastroenterology & Hepatology
|
February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study
Pietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2021
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
Chun Jen Liu, I Shyan Sheen, Chi Yi Chen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B
Man-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
The American Journal of Gastroenterology
|
May 22, 2024
Bleeding Risk of Cold Versus Hot Snare Polypectomy for Pedunculated Colorectal Polyps Measuring 10 mm or Less: Subgroup Analysis of a Large Randomized Controlled Trial
Cheng-Hao Tseng, Li-Chun Chang, Jia-Ling Wu, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 132) with videos related to
Sort By:
Page
of 14
The Lancet. Gastroenterology & Hepatology
|
June 20, 2024
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
Harry L A Janssen, Young-Suk Lim, Pietro Lampertico, et al.
Journal of Gastroenterology and Hepatology
|
November 14, 2025
Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Yun-Chu Chen, Yu-Ping Chang, Ji-Yuh Lee, et al.
Alimentary Pharmacology & Therapeutics
|
October 31, 2023
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks
Scott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, et al.
Journal of Medical Virology
|
January 15, 2026
Effect of Glycated Hemoglobin Levels on Serum Mac-2 Binding Protein Glycosylation Isomer in the Diagnosis of Hepatitis C-Virus Related Hepatic Fibrosis
Yu-Ping Chang, Yun-Chu Chen, Ji-Yuh Lee, et al.
Nature Medicine
|
June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Stephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Gut
|
January 20, 2026
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease
Yu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, et al.
The Lancet. Gastroenterology & Hepatology
|
February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study
Pietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 5, 2021
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
Chun Jen Liu, I Shyan Sheen, Chi Yi Chen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 27, 2022
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B
Man-Fung Yuen, Chi-Yi Chen, Chun-Jen Liu, et al.
The American Journal of Gastroenterology
|
May 22, 2024
Bleeding Risk of Cold Versus Hot Snare Polypectomy for Pedunculated Colorectal Polyps Measuring 10 mm or Less: Subgroup Analysis of a Large Randomized Controlled Trial
Cheng-Hao Tseng, Li-Chun Chang, Jia-Ling Wu, et al.
Page
of 14